The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price isnât letting the market weakness hold it back today.
In morning trade, the biopharmaceutical companyâs shares are up 20% to $1.15.
Why is the Paradigm share price surging higher?
The catalyst for the strong rise by the Paradigm share price on Thursday has been the release of a positive announcement.
According to the release, the company has received official acceptance of an Australian patent application for the âtreatment of bone marrow pathologies with polysulfated polysaccharides.â
Paradigmâs patent will expire in over 15 years on 6 August 2038.
The release notes that the first claim of the accepted patent refers to a method of improving knee function where the subject has a bone marrow lesion and osteoarthritis in a knee by administering pentosan polysulfate sodium (PPS).
It is also worth noting that there is only one FDA approved manufacturer of PPS, Bene pharmaChem. Pleasingly, Paradigm has an exclusive, sub-licensable, global supply agreement with Bene pharmaChem for the manufacture and commercial use of PPS for multiple indications extending for 25 years post first marketing approval.
What about in the US?
Readers may recall that earlier this year the company revealed that the US patent office rejected its patent application.
However, the release notes that this Australian patent was the same one the US rejected. Furthermore, the US rejection was not a final rejection.
In light of this, the market appears optimistic that Paradigmâs next attempt to get its US patent application accepted may be successful. Paradigm intends to file its response to the US patent and trademark office by the end of July.
Paradigmâs Chairman, Paul Rennie commented:
It is very exciting for the Companyâs strategic plans to have a patent which claims the treatment of people with osteoarthritis and bone marrow lesions with pentosan polysulphate sodium (PPS) and we expect further acceptance and grants in other territories in the coming months. We continue to work in partnership with our patent attorneys to proactively prosecute new patents to extend our protection on the use of PPS in disease indications with unmet medical needs.
The post Why is the Paradigm share price rocketing 20% higher today? appeared first on The Motley Fool Australia.
Should you invest $1,000 in Paradigm Biopharmaceuticals Ltd right now?
Before you consider Paradigm Biopharmaceuticals Ltd, you’ll want to hear this.
Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Paradigm Biopharmaceuticals Ltd wasn’t one of them.
The online investing service heâs run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.
See The 5 Stocks
*Returns as of June 1 2022
(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}
setButtonColorDefaults(“#43B02A”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#43B02A”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()
More reading
Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
from The Motley Fool Australia https://ift.tt/FGeOr0v
Leave a Reply